PepsiCo acquires prebiotic soda brand Poppy for $1.95B as traditional soda faces health-driven decline

Summary

PepsiCo is acquiring prebiotic soda brand Poppy for $1.95 billion. The deal includes $300 million in anticipated cash tax benefits from an asset step-up. When PepsiCo acquires Poppy as an LLC, it can step up the basis of the target's assets to reflect the difference between purchase price and book value. Because much of Poppy's value is brand equity rather than balance sheet assets, that step-up is substantial. PepsiCo can then amortize the stepped-up value over time, reducing taxable earnings and generating tax deductions. The $300 million figure represents the present value of those future tax savings, meaning PepsiCo was willing to pay an extra $300 million to capture those deductions instead of acquiring Poppy as a C Corporation.

Traditional soda is under sustained attack. RFK Jr., now Health and Human Services secretary, has called soda "poison." Sales of conventional cola have stalled. Poppy and competitor Olipop have built meaningful market share by positioning prebiotic sodas as a healthier alternative. Each can contains 25 calories and inulin fiber from agave or chicory roots that feeds existing gut bacteria. Unlike probiotic drinks like kombucha or kefir, which introduce new microbes, prebiotics work with the body's existing microbiome, a pitch that has resonated with consumers.

Poppy's growth velocity outpaced the seltzer boom that preceded it. Brands like Spindrift and LaCroix put pressure on traditional soda, but prebiotic sodas have scaled faster and captured consumer attention more completely. The brand execution was sharp, with strong packaging, flavor variety, and rapid iteration. Poppy reportedly rebranded from an apple cider vinegar tonic after Olipop launched a prebiotic soda with similar branding and positioning. The company scaled to a $2 billion acquisition in a compressed timeframe.

Big Soda is now playing defense. Coca-Cola announced in February it would launch Simply Pop, a digestive-aid soda, while PepsiCo had been developing its own spring launch, though the Poppy acquisition likely renders that redundant. Acquiring Poppy lets PepsiCo fold the brand into its portfolio, keep the product off shelves as standalone competition, and leverage its global distribution network to scale the brand far beyond what an independent company could achieve.

Poppy represents a rare, outsized exit for venture-backed CPG founders. Building soda brands requires relentless execution across manufacturing, distribution, retail placement, and marketing over years. There are no network effects, no viral mechanics, no high-margin referral loops. Success depends on grit, sales, and advertising spend. The prebiotic soda category proved the model worked and attracted a buyer with unmatched distribution. Replicating that outcome requires deep operational discipline and patient capital.